logo
  

Aprea : Phase 1/2 Trial On TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

Aprea Therapeutics Inc. (APRE) said that the phase 1/2 trial, which evaluated the frontline treatment of eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant acute myeloid leukemia or AML, has met the pre-specified primary efficacy endpoint of complete remission or CR rate.

In Wednesday pre-market, APRE was trading at $6.88 up $2.03 or 41.86%.

In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37% and the composite response rate of CR plus CR with incomplete hematologic recovery or CRi, CR/CRi, was 53%.

The trial met the primary efficacy endpoint of CR, which is based on a Simon 2-stage design. As of the data cut, 11 patients remain on study treatment and continue to be followed for safety and efficacy.

The company plans to discuss the dataset with the U.S. Food and Drug Agency (FDA) in the second half of 2021 and expects to present data from the trial at a future scientific or medical conference.

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. The mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

Acute myeloid leukemia is the most common form of adult leukemia, with the highest incidence in patients aged 60 years and older. AML is characterized by proliferation of abnormal immature white blood cells that impairs production of normal blood cells.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,... CVS Health said it has installed time delay safe technology in all 392 Illinois CVS Pharmacy locations, including those in Target stores, to help reduce organized retail crime. The installation of new safes for controlled substances are anticipated to help prevent pharmacy robberies. There is also potential for associated diversion of controlled substance medications, including opioid medications.
Follow RTT